The role of targeted therapy in non-small cell lung cancer

Maione, Paolo; Rossi, Antonio; Airoma, Giuseppe; Ferrara, Carmine; Castaldo, Vincenzo; Gridelli, Cesare

doi:10.1016/j.critrevonc.2004.02.002

Cited by 23 publications

(13 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the A549 lung cancer cells showed the highest antigen 14C5 expression, providing a possible new target for non -small cell lung cancer (NSCLC) therapy. Although breast cancer is currently second as the leading cancer causing death in women in the United States, lung cancer is the leading cause of cancer-related mortality in both men and women, with NSCLC accounting for f80% of all lung cancers (9,23,24). Today, the therapy of NSCLC has reached a plateau in improving patient survival (24).…”

Section: Discussionmentioning

confidence: 99%

“…Although breast cancer is currently second as the leading cancer causing death in women in the United States, lung cancer is the leading cause of cancer-related mortality in both men and women, with NSCLC accounting for f80% of all lung cancers (9,23,24). Today, the therapy of NSCLC has reached a plateau in improving patient survival (24). Further investigation on NSCLC-related antigen 14C5 expression is necessary and may result in antigen 14C5 as a new target for NSCLC therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model

Burvenich¹,

Schoonooghe²,

Cornelissen³

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose:The monoclonal antibody (mAb) 14C5 is a murine IgG1directed against a yet undefined molecule involved in cell substrate adhesion found on the surface of malignant breast cancer tissue. mAb 14C5 is able to inhibit cell substrate adhesion and invasion of breast cancer cells in vitro. In normal tissues as well as in the stroma surrounding in situ carcinomas of the breast, no expression of the antigen 14C5 occurs. The aim of this study was to investigate the in vitro and in vivo targeting properties of

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model

Burvenich¹,

Schoonooghe²,

Cornelissen³

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The most common form of lung cancer is non-small cell lung cancer (NSCLC) that includes large cell lung cancer, squamous cell carcinoma and adenocarcinoma (Maione et al 2004). Treatment outcomes for NSCLC still remain poor, although a number of biological agents, both single agents and combined with other conventional treatment modalities such as chemotherapy and radiotherapy, were evaluated (Hoang et al 2002;Sandler 2003;Maione et al 2004). …”

Section: Introductionmentioning

confidence: 99%

Modulation of cell proliferation and differentiation of human lung carcinoma cells by the interferon-alpha

Krejčová¹,

Procházková²,

Kubala³

et al. 2009

gpb

View full text Add to dashboard Cite

Abstract. Treatments of non-small cell lung cancer (NSCLC), the most common form of lung cancer, still remain poor. Interferon alpha (IFN-α), an important physiological immunomodulator, possesses direct cytotoxic and cytostatic effects on tumour cells, antiangiogenic effects, and activates anti-tumour immunity. Recently, the IFN-α oncologic indications have included melanoma, renal carcinoma, and different types of leukaemia. However, the application of IFN-α in therapy of lung cancer has not been validated yet. Herein the human lung carcinoma cell line A549, a model of NSCLC in vitro, was used to pursue the effect of IFN-α on A549 cell proliferation and differentiation together with the effect on protein expression and activity of three ATP-transporters mediating multi-drug resistance (MDR). IFN-α significantly inhibited the proliferation of A549 cells which was not connected with arrest in a particular cell cycle phase. Further, IFN-α-mediated differentiation of A549 was observed based on an increase in alkaline phosphatase activity. Simultaneously, IFN-α increased the expression and activity of ATP-transporters mediating MDR. Thus, the IFN-α down-regulation of NSCLC cell proliferation was accompanied by a potential of cells to exclude potential therapeutic substances such as chemotherapeutic agents. These effects could have a significant impact on considerations of IFN-α as a therapeutic agent for NSCLC.

show abstract

“…6,7 Unfortunately, gene therapy strategies restoring p53 alone or in combination with chemotherapy failed to improve the outcome of the patients. 8 A new class of biologically active agents in lung cancers are proteasome inhibitors. Bortezomib is a dipeptide boronic acid and a potent, highly selective and reversible inhibitor of the 26S proteasome.…”

Section: Introductionmentioning

confidence: 99%

The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells

et al. 2007

View full text Add to dashboard Cite

In this report, the effects of a combined treatment with the proteasome inhibitor bortezomib and either a recombinant adenoassociated virus type 2 (rAAV-2)-mediated p53 gene transfer or chemotherapeutic agents, docetaxel and pemetrexed, were tested on p53 positive and p53negative non-small cell lung cancer (NSCLC) cell lines. The combination of bortezomib and rAAV-p53 led to a significant synergistic inhibition of cell growth between 62-82% depending on the p53 status of the cell line and drug concentration. Surviving cells of the combined treatment showed a significant reduced ability to form colonies. Enhanced cell toxicity was associated with a 5.3-14.4-fold increase of the apoptotic rate and intracellular p53 level up to 50.4% following vectormediated p53 restoration and bortezomib treatment. In contrast, an antagonistic effect on tumor cell growth and colony formation was observed for the combination of bortezomib and docetaxel or pemetrexed as a reduction of cell growth between 31 and 48% was found in comparison to 50% using the single agents. Lower cytotoxic effects were associated with significantly reduced apoptosis and an increase of clonogenic growth. The observed antagonistic effects between bortezomib and docetaxel or pemetrexed might influence clinical trials using these compounds. Conversely, p53 restoration and bortezomib treatment led to enhanced, synergistic tumor cell toxicity.

show abstract

The role of targeted therapy in non-small cell lung cancer

Cited by 23 publications

References 76 publications

In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model

In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131–Labeled Monoclonal Antibody 14C5 in a Non–Small Cell Lung Cancer and Colon Carcinoma Model

Modulation of cell proliferation and differentiation of human lung carcinoma cells by the interferon-alpha

The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells

Contact Info

Product

Resources

About